Advanced Human & Humanized Single Domain Antibody (SdAb) Discovery Service

Q: What is the main difference between 'human' and 'humanized' sdAbs?

A 'human' sdAb is discovered directly from a human antibody library, meaning its entire sequence is of human origin. A 'humanized' sdAb originates from another species (like a llama) and has been engineered to be more 'human-like' by grafting its CDRs onto a human framework, thereby reducing its potential to cause an immune reaction.

Background Platform Technology Workflow Advantage Related Services FAQ Online Inquiry

Creative Biolabs is your strategic partner in pioneering the future of biologics. We specialize in the discovery and development of single domain antibodies (sdAbs) with a critical focus on clinical translatability. Our world-class services provide access to fully human sdAbs or expertly humanized V_HHs, engineered to exhibit high affinity, specificity, and superior developability while minimizing the risk of immunogenicity.

Discuss Your Project Today

The Unparalleled Potential of Single Domain Antibodies

Single domain antibodies, the smallest functional antibody fragments derived from the variable heavy-chain domains of camelid heavy-chain-only antibodies (V_HH) or cartilaginous fish (VNAR), are revolutionizing drug discovery. However, as most sdAbs originate from non-human species (llamas, alpacas), they can elicit an anti-drug antibody (ADA) response in patients. This immunogenicity can compromise efficacy and safety, presenting a significant hurdle for therapeutic development.

Creative Biolabs' solution is two-fold:

Direct Discovery of Fully Human SdAbs: By screening our proprietary, large-scale human sdAb antibody libraries, we can directly isolate high-affinity human sdAbs, completely bypassing the need for humanization.
State-of-the-Art V_HH Humanization: For projects starting with an exceptional camelid V_HH, our sophisticated humanization platforms reduce immunogenicity while preserving the original antibody's affinity and specificity.

Our Premier Service Platforms for Human & Humanized SdAb Discovery

With over 20 years of leadership in antibody engineering, Creative Biolabs offers a suite of advanced platforms tailored to your project's specific needs.

Direct Discovery of Fully Human Single Domain Antibodies

Eliminate immunogenicity concerns from the start. We identify potent, fully human sdAbs by screening our exceptionally diverse, pre-constructed human libraries.

Human SdAb Phage Display Libraries: Our libraries boast a diversity exceeding 10¹¹ unique clones, ensuring comprehensive epitope coverage and the identification of rare, high-affinity binders against the most challenging targets.
Human SdAb Yeast Display Libraries: Ideal for fine-tuning and selecting antibodies with optimal biophysical properties. Yeast display allows for precise affinity-based screening using FACS, leading to sdAbs with superior stability and expression profiles.

Expert Humanization of Camelid V_HH Antibodies

When you have a lead camelid V_HH with unparalleled function, our humanization service is the gold standard for preparing it for clinical evaluation. Our process is a meticulous, multi-step approach that goes far beyond simple CDR grafting.

Our Humanization Strategies

Sequence Analysis & 3D Modeling: We perform in-depth sequence alignment against human germline frameworks and build high-resolution 3D structural models of the parent V_HH.
Advanced CDR Grafting: The three Complementarity-Determining Regions (CDRs) are precisely grafted onto the most suitable human VH acceptor framework.
Framework Optimization via Back-Mutations: Using sophisticated computational algorithms, we identify critical framework residues from the original V_HH that are essential for maintaining the CDR loop conformation and antigen binding. These are selectively re-introduced into the human framework.
Veneering/Resurfacing: We analyze the surface-exposed residues of the V_HH and replace non-human residues with their closest human counterparts, further reducing potential B-cell epitopes without disturbing the antibody core.
In Silico Immunogenicity Prediction: We utilize state-of-the-art software to predict potential T-cell epitopes in the humanized sequence, allowing for proactive amino acid substitutions to de-risk the final molecule.

Fig. 1 An example of a general strategy to humanize sdAbs. (OA Literature). Fig. 1 Schematic overview of the single domain antibody humanization strategy.¹

Leveraging Next-Generation Technologies for Superior Outcomes

We integrate cutting-edge technologies throughout our discovery and engineering workflow to accelerate timelines and enhance the quality of your sdAb candidates.

Technology Platform	Key Advantages	Best For...
Phage Display	Massive library diversity, robust selection protocols, cost-effective screening.	Initial discovery of a broad panel of human or humanized sdAb hits.
Yeast Display	Precise affinity discrimination (FACS), direct screening for stability & expression.	Affinity maturation, developability optimization, screening complex targets.
Next-Generation Sequencing (NGS)	Deep sequencing of library outputs, comprehensive analysis of clone diversity and enrichment.	Identifying rare clones, tracking antibody lineage, ensuring library quality.
Computational Biology & AI	In silico 3D modeling, binding energy calculation, immunogenicity prediction.	Rational design of humanized variants, optimizing biophysical properties.
Surface Plasmon Resonance (SPR) & BLI	Real-time, label-free kinetics and affinity measurement.	Characterizing and validating lead candidates with high precision.

A Seamless Project Workflow of Human & Humanized SdAb Discovery

Our process is designed to be transparent, collaborative, and efficient.

Project Consultation: Our Ph.D.-level scientists work with you to understand your target, goals, and define the optimal discovery strategy.
Library Screening or Humanization Design: We execute the chosen strategy—either screening our human libraries or designing humanized variants of your V_HH.
Hit Generation & Validation: A panel of unique sdAb binders is identified and validated for target-specific binding using ELISA.
Sequencing & Expression: Hits are sequenced (with NGS analysis) and produced in our high-yield microbial or mammalian expression systems.
In-depth Characterization: Lead candidates undergo rigorous biophysical and functional characterization, including affinity measurement (SPR/BLI), stability analysis, and epitope binning.
Deliverables: You receive purified antibodies, a comprehensive report detailing all methods and results, and the full sequence information for your lead candidates.

Why Choose Creative Biolabs?

Unmatched Expertise: Over two decades of dedicated experience in antibody discovery and engineering.
Minimized Immunogenicity: Access fully human sdAbs or benefit from our best-in-class humanization platform for reduced clinical risk.
Guaranteed Affinity: We deliver humanized sdAbs with affinity that is equal to or even improved compared to the parental antibody.
Superior Developability: Our screening and engineering processes are designed to select for candidates with excellent stability, solubility, and production yield.
Comprehensive Platforms: A true one-stop solution, from initial discovery through to full characterization and large-scale production.
IP Protection: You retain full intellectual property rights to your discovered and developed antibody candidates.

Related Featured SdAb Discovery Services

Explore our specialized services to advance your research:

Ready to advance your project with a high-affinity, low-immunogenicity single domain antibody? Our team of experts is ready to discuss your target and design a custom service plan.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQ)

Q1: What is the main difference between "human" and "humanized" sdAbs?

A: A "human" sdAb is discovered directly from a human antibody library, meaning its entire sequence is of human origin. A "humanized" sdAb originates from another species (like a llama) and has been engineered to be more "human-like" by grafting its CDRs onto a human framework, thereby reducing its potential to cause an immune reaction.

Q2: What is the typical timeline for a humanized V_HH discovery project?

A: While timelines can vary based on project complexity, a standard humanization and validation project typically takes between 10-14 weeks from sequence receipt to delivery of characterized candidates.

Q3: What starting material do I need to provide for a humanization project?

A: Ideally, you would provide the amino acid or DNA sequence of the parental V_HH and any characterization data you have, such as its binding affinity for the target antigen.

Q4: Will the humanization process affect my antibody's affinity?

A: Our primary goal is to preserve or even improve affinity. Our advanced computational modeling and rational back-mutation strategy are specifically designed to maintain the integrity of the antigen-binding site, ensuring high-affinity binding is retained. We validate this with SPR/BLI analysis.

Reference

Vincke, Cecile, et al. "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized single domain antibody scaffold." Journal of Biological Chemistry 284.5 (2009): 3273-3284. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1074/jbc.M806889200

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.